FIELD: biotechnology.
SUBSTANCE: invention relates to a bispecific antibody specifically binding to a human vascular endothelial growth factor-VEGF and human angiopoietin-2-ANG-2, a pharmaceutical composition containing it, as well as a method for its preparation. Also a nucleic acid encoding the above antibody and a vector or host cell containing the aforementioned nucleic acid are disclosed.
EFFECT: invention allows effective treatment of cancer and/or vascular diseases.
12 cl, 19 dwg, 18 tbl, 20 ex
Title | Year | Author | Number |
---|---|---|---|
BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2009 |
|
RU2542382C2 |
BISPECIFIC BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2011 |
|
RU2597973C2 |
ANTIBODIES AGAINST HUMAN ANGIOPOIETIN-2 | 2009 |
|
RU2569107C2 |
ANTIBODIES AGAINST HUMAN ANGIOPOIETIN-2 | 2009 |
|
RU2569461C2 |
BISPECIFIC ANTIGEN-BINDING PROTEINS | 2010 |
|
RU2573914C2 |
TRI- OR TETRASPECIFIC ANTIBODIES | 2010 |
|
RU2570633C2 |
BISPECIFIC, TETRAVALENT ANTIGEN BINDING PROTEINS | 2010 |
|
RU2604189C2 |
BISPECIFIC ANTIBODIES | 2011 |
|
RU2573588C2 |
COMPOSITION CONTAINING ANTIBODY | 2019 |
|
RU2806628C2 |
VARIANTS OF Fc-REGION WITH IMPROVED ABILITY TO BIND TO PROTEIN A | 2015 |
|
RU2698969C2 |
Authors
Dates
2017-12-27—Published
2014-12-09—Filed